ESMO Breast Cancer Spotlight

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress.

Melanie Royce, MD, details recent studies into hormone receptor-positive (HR+) and HER2-advanced breast cancer treatment.

Sara Hurvitz, MD, discusses the results from a preplanned interim analysis in HR+, HER2-negative breast cancer.

Findings of a recent multicenter randomized trial^ showed postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer (MBC) had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to endocrine therapy.